Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Medical and Biomechanical Risk Factors for Incident Bone Stress Injury in Collegiate Runners: Can Plantar Pressure Predict Injury?

Authors:
Andrew R Wilzman Adam S Tenforde Karen L Troy Kenneth Hunt Nathaniel Fogel Megan Deakins Roche Emily Kraus Rishi Trikha Scott Delp Michael Fredericson

Orthop J Sports Med 2022 Jun 15;10(6):23259671221104793. Epub 2022 Jun 15.

Stanford Medical Center, Redwood City, California, USA.

Background: Bone stress injury (BSI) is a common reason for missed practices and competitions in elite track and field runners.

Hypothesis: It was hypothesized that, after accounting for medical risk factors, higher plantar loading during running, walking, and athletic movements would predict the risk of future BSI in elite collegiate runners.

Study Design: Cohort study; Level of evidence, 2.

Methods: A total of 39 elite collegiate runners (24 male, 15 female) were evaluated during the 2014-2015 academic year to determine the degree to which plantar pressure data and medical history (including Female and Male Athlete Triad risk factors) could predict subsequent BSI. Runners completed athletic movements while plantar pressures and contact areas in 7 key areas of the foot were recorded, and the measurements were reported overall and by specific foot area. Regression models were constructed to determine factors related to incident BSI.

Results: Twenty-one runners (12 male, 9 female) sustained ≥1 incident BSI during the study period. Four regression models incorporating both plantar pressure measurements and medical risk factors were able to predict the subsequent occurrence of (A) BSIs in female runners, (B) BSIs in male runners, (C) multiple BSIs in either male or female runners, and (D) foot BSIs in female runners. Model A used maximum mean pressure (MMP) under the first metatarsal during a jump takeoff and only misclassified 1 female with no BSI. Model B used increased impulses under the hindfoot and second through fifth distal metatarsals while walking, and under the lesser toes during a cutting task, correctly categorizing 83.3% of male runners. Model C used higher medial midfoot peak pressure during a shuttle run and triad cumulative risk scores and correctly categorized 93.3% of runners who did not incur multiple BSIs and 66.7% of those who did. Model D included lower hindfoot impulses in the shuttle run and higher first metatarsal MMP during treadmill walking to correctly predict the subsequent occurrence of a foot BSI for 75% of women and 100% without.

Conclusion: The models collectively suggested that higher plantar pressure may contribute to risk for BSI.

Download full-text PDF

 Source
http://dx.doi.org/10.1177/23259671221104793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208063PMC
June 2022

Publication Analysis

Top Keywords

risk factors
16
plantar pressure
16
predict subsequent
12
female runners
12
male female
12
runners
10
athletic movements
8
regression models
8
factors predict
8
runners model
8
subsequent occurrence
8
runners male
8
higher plantar
8
collegiate runners
8
multiple bsis
8
stress injury
8
bone stress
8
medical risk
8
male runners
8
bsis male
8

Keyword Occurance

Similar Publications

Safety of Statins and Nonstatins for Treatment of Dyslipidemia.

Authors:
Connie B Newman

Endocrinol Metab Clin North Am 2022 Sep 8;51(3):655-679. Epub 2022 Jul 8.

Division of Endocrinology, Diabetes and Metabolism, New York University Grossman School of Medicine, 435 East 30th street, Sixth floor, New York, NY 10016, USA. Electronic address:

This article reviews the safety of statins and non-statin medications for management of dyslipidemia. Statins have uncommon serious adverse effects: myopathy/ rhabdomyolysis, which resolve with statin discontinuation, and diabetes, usually in people with risk factors for diabetes. The CVD benefit of statins far exceeds the risk of diabetes. Read More

View Article and Full-Text PDF
September 2022
Similar Publications

Dyslipidemia in Diabetes: When and How to Treat?

Authors:
Ronald B Goldberg

Endocrinol Metab Clin North Am 2022 Sep 4;51(3):603-624. Epub 2022 Jul 4.

Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, 1450 Northwest 10th Avenue, Miami, FL 33136, USA. Electronic address:

Elevated triglyceride and reduced high-density lipoprotein cholesterol (HDL-C) are common in type 2 diabetes, but increased atherogenic particles and dysfunctional HDL are demonstrable in both types 1 and 2 diabetes, contributing to a two-fold increase in atherosclerotic cardiovascular disease (ASCVD). ASCVD risk accelerates with diabetes duration and severity, aging, risk factors, and risk enhancers. Using statins or other LDL-C-lowering agents if needed in adults with intermediate or greater degrees of risk is recommended. Read More

View Article and Full-Text PDF
September 2022
Similar Publications

Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents.

Authors:
Amisha Patel Nivedita Patni

Endocrinol Metab Clin North Am 2022 Sep 4;51(3):573-588. Epub 2022 Jul 4.

Division of Pediatric Endocrinology, Department of Pediatrics, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063, USA. Electronic address:

Cardiovascular disease (CVD) is the leading cause of mortality in the United States. Universal screening in all children aged 9 to 11 years and 17 to 21 years, and targeted screening in children with high-risk factors, can help in early identification and treatment of dyslipidemia during the youth, significantly reducing clinical CVD risk in adult life. Lifestyle modifications with heart-healthy diet and moderate-vigorous activity are fundamental in the management of pediatric dyslipidemia. Read More

View Article and Full-Text PDF
September 2022
Similar Publications

Assessment of Cardiovascular Disease Risk: A 2022 Update.

Authors:
Earl Goldsborough Ngozi Osuji Michael J Blaha

Endocrinol Metab Clin North Am 2022 Sep 4;51(3):483-509. Epub 2022 Jul 4.

Division of Cardiology, Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Assessment of atherosclerotic cardiovascular disease (ASCVD) risk is the cornerstone of primary ASCVD prevention, enabling targeted use of the most aggressive therapies in those most likely to benefit, while guiding a conservative approach in those who are low risk. ASCVD risk assessment begins with the use of a traditional 10-year risk calculator, with further refinement through the consideration of risk-enhancing factors (particularly lipoprotein(a)) and subclinical atherosclerosis testing (particularly coronary artery calcium (CAC) testing). In this review, we summarize the current field of ASCVD risk assessment in primary prevention and highlight new guidelines from the Endocrine Society. Read More

View Article and Full-Text PDF
September 2022
Similar Publications

NAFLD: genetics and its clinical implications.

Authors:
Dixa Sharma Palash Mandal

Clin Res Hepatol Gastroenterol 2022 Aug 10:102003. Epub 2022 Aug 10.

P.D. Patel Institute of Applied Science, Charusat University of Science and Technology, Changa Dist, Anand, Gujarat, 388421, India. Electronic address:

Worldwide non-alcoholic fatty liver disease (NAFLD) is recognized as the most common type of liver disease and its burden increasing at an alarming rate. NAFLD entails steatosis, fibrosis, cirrhosis, and, finally, hepatocellular carcinoma (HCC). The substantial inter-patient variation during disease progression is the hallmark of individuals with NAFLD. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}